Global Insulin Resistance Pipeline Insights Report 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Insulin Resistance-Pipeline Insights, 2016" report to their offering.

Insulin Resistance-Pipeline Insights, 2016 provides in depth insight on the pipeline drugs and their development activities around the Insulin Resistance. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

The report covers the product clinical trials information and other development activities including technology, licensing, collaboration, acquisitions, funding, patent and USFDA & EMA designations details. The Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Insulin Resistance.

The report also assesses the Insulin Resistance therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope of the report:

- The report provides competitive pipeline landscape of Insulin Resistance

- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

- Coverage of the Insulin Resistance pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

- The report review the key players involved in the therapeutics development for Insulin Resistance and also provides company profiling

- The report also gives the information on dormant and discontinued pipeline projects

- Pipeline products coverage based on various stages of development ranging from pre registration till discovery and undisclosed stages

- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Insulin Resistance Overview
  2. Insulin Resistance Pipeline Therapeutics
  3. Insulin Resistance Therapeutics under Development by Companies
  4. Insulin Resistance Filed and Phase III Products
  5. Comparative Analysis
  6. Insulin Resistance Phase II Products
  7. Comparative Analysis
  8. Insulin Resistance Phase I and IND Filed Products
  9. Comparative Analysis
  10. Insulin Resistance Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Insulin Resistance - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Insulin Resistance - Discontinued Products
  19. Insulin Resistance - Dormant Products
  20. Companies Involved in Therapeutics Development for Insulin Resistance
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/ptghdl/insulin

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals